Cogent Biosciences, Inc. (COGT) EBITDA
- 2026-06-30: Basis Reported; EBITDA (m); Operating income -$102.64M; Depreciation and amortization (m).
- 2026-03-31: Basis Reported; EBITDA (m); Operating income -$103.61M; Depreciation and amortization (m).
- 2025-09-30: Basis Reported; EBITDA (m); Operating income -$83.36M; Depreciation and amortization (m).
- 2025-06-30: Basis Reported; EBITDA (m); Operating income -$75.58M; Depreciation and amortization (m).
Historical EBITDA
EBITDA 3 month
| Date | Basis | EBITDA | Operating income | Depreciation and amortization | Revenue | EBITDA margin | Capital spending | Operating cash flow | Cost of products and services | Research and development | Selling, general and administration | Income tax expense / benefit |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026-06-30 | Reported | (m) | -$102.64M | (m) | (m) | (m) | $370.00K* | -$77.27M* | (m) | $70.81M | (m) | (m) |
| 2026-03-31 | Reported | (m) | -$103.61M | (m) | (m) | (m) | $449.00K | -$86.88M | (m) | $75.36M | (m) | (m) |
| 2025-09-30 | Reported | (m) | -$83.36M | (m) | (m) | (m) | $65.00K* | -$64.29M* | (m) | $68.99M | (m) | (m) |
| 2025-06-30 | Reported | (m) | -$75.58M | (m) | (m) | (m) | $131.00K* | -$54.54M* | (m) | $62.20M | (m) | (m) |
| 2025-03-31 | Reported | (m) | -$74.93M | (m) | (m) | (m) | $547.00K | -$66.51M | (m) | $63.03M | (m) | (m) |
| 2024-09-30 | Reported | (m) | -$75.41M | (m) | (m) | (m) | $280.00K* | -$51.98M* | (m) | $63.61M | (m) | (m) |
| 2024-06-30 | Reported | (m) | -$64.39M | (m) | (m) | (m) | $148.00K* | -$42.70M* | (m) | $54.29M | (m) | (m) |
| 2024-03-31 | Reported | (m) | -$62.40M | (m) | (m) | (m) | $70.00K | -$52.53M | (m) | $52.70M | (m) | (m) |
| 2023-09-30 | Reported | (m) | -$59.58M | (m) | (m) | (m) | $121.00K* | -$37.97M* | (m) | $50.13M | (m) | (m) |
| 2023-06-30 | Reported | (m) | -$47.09M | (m) | (m) | (m) | $1.26M* | -$32.07M* | (m) | $38.87M | (m) | (m) |
| 2023-03-31 | Reported | (m) | -$43.24M | (m) | (m) | (m) | $1.10M | -$39.52M | (m) | $36.04M | (m) | (m) |
| 2022-09-30 | Reported | (m) | -$36.82M | (m) | (m) | (m) | $3.31M* | -$34.44M* | (m) | $29.94M | (m) | (m) |
| 2022-06-30 | Reported | (m) | -$35.85M | (m) | (m) | (m) | $1.14M* | -$26.46M* | (m) | $29.48M | (m) | (m) |
| 2022-03-31 | Reported | (m) | -$31.42M | (m) | (m) | (m) | $441.00K | -$28.33M | (m) | $25.47M | (m) | (m) |
| 2021-09-30 | Reported | (m) | -$19.82M | (m) | (m) | (m) | $1.16M* | -$14.11M* | (m) | $14.80M | (m) | (m) |
| 2021-06-30 | Reported | (m) | -$17.29M | (m) | (m) | (m) | (m) | -$12.51M* | (m) | $12.39M | (m) | (m) |
| 2021-03-31 | Reported | (m) | -$12.80M | (m) | (m) | (m) | (m) | -$11.37M | (m) | $8.21M | (m) | (m) |
| 2020-09-30 | Reported | (m) | -$57.20M | (m) | (m) | (m) | (m) | -$10.27M* | (m) | $5.00M | (m) | (m) |
| 2020-06-30 | Reported | (m) | -$7.40M | (m) | (m) | (m) | (m) | -$8.32M* | (m) | $5.13M | (m) | (m) |
| 2020-03-31 | Reported | (m) | -$6.14M | (m) | (m) | (m) | (m) | -$7.89M | (m) | $9.50M | (m) | (m) |
| 2019-12-31 | Reported | (m) | $2.24M | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2019-09-30 | Reported | (m) | -$12.04M | (m) | (m) | (m) | -$22.00K* | -$10.21M* | (m) | $10.34M | (m) | (m) |
| 2019-06-30 | Reported | (m) | -$10.54M | (m) | (m) | (m) | $0.00* | -$11.34M* | (m) | $10.62M | (m) | (m) |
| 2019-03-31 | Reported | (m) | -$11.84M | (m) | (m) | (m) | $42.00K | -$11.52M | (m) | $12.40M | (m) | (m) |
| 2018-12-31 | Reported | (m) | -$9.00M | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2018-09-30 | Reported | (m) | -$10.58M | (m) | (m) | (m) | $86.00K* | -$7.58M* | (m) | $10.25M | (m) | $0.00 |
| 2018-06-30 | Reported | (m) | -$9.44M | (m) | (m) | (m) | $388.00K* | -$7.91M* | (m) | $9.13M | (m) | $0.00 |
| 2018-03-31 | Reported | (m) | -$6.99M | (m) | (m) | (m) | $75.00K | -$7.98M | (m) | $8.14M | (m) | $0.00 |
| 2017-12-31 | Reported | (m) | -$6.88M | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2017-09-30 | Reported | (m) | -$7.17M | (m) | (m) | (m) | $275.00K* | -$6.29M* | (m) | $8.18M | (m) | $0.00 |
| 2017-06-30 | Reported | (m) | -$6.03M | (m) | (m) | (m) | $217.00K* | (m) | (m) | $7.14M | (m) | $0.00 |
| 2017-03-31 | Reported | (m) | -$6.07M | (m) | (m) | (m) | $320.00K | (m) | (m) | $6.95M | (m) | $0.00 |
EBITDA 12 month
| Date | Basis | EBITDA | Operating income | Depreciation and amortization | Revenue | EBITDA margin | Capital spending | Operating cash flow | Cost of products and services | Research and development | Selling, general and administration | Income tax expense / benefit |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2025-12-31 | Reported | (m) | -$333.36M | (m) | (m) | (m) | $1.55M | -$264.44M | (m) | $269.78M | (m) | $0.00 |
| 2024-12-31 | Reported | (m) | -$275.94M | (m) | (m) | (m) | $573.00K | -$207.79M | (m) | $232.66M | (m) | (m) |
| 2023-12-31 | Reported | (m) | -$208.13M | (m) | (m) | (m) | $2.80M | -$153.62M | (m) | $173.75M | (m) | (m) |
| 2022-12-31 | Reported | (m) | -$147.84M | (m) | (m) | (m) | $6.86M | -$118.64M | (m) | $121.63M | (m) | (m) |
| 2021-12-31 | Reported | (m) | -$75.55M | (m) | (m) | (m) | $1.72M | -$58.76M | (m) | $55.91M | (m) | (m) |
| 2020-12-31 | Reported | (m) | -$82.20M | (m) | (m) | (m) | (m) | -$35.85M | (m) | $25.74M | (m) | (m) |
| 2020-09-30 | Rolling | (m) | -$68.50M* | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2020-06-30 | Rolling | (m) | -$23.34M* | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2020-03-31 | Rolling | (m) | -$26.48M* | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2019-12-31 | Reported | (m) | -$32.18M | (m) | (m) | (m) | $33.00K | -$41.51M | (m) | $43.71M | (m) | (m) |
| 2019-12-31 | Rolling | (m) | -$32.18M* | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2019-09-30 | Rolling | (m) | -$43.42M* | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2019-06-30 | Rolling | (m) | -$41.96M* | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2019-03-31 | Rolling | (m) | -$40.86M* | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2018-12-31 | Reported | (m) | -$36.01M | (m) | (m) | (m) | $549.00K | -$32.49M | (m) | $38.28M | (m) | (m) |
| 2018-12-31 | Rolling | (m) | -$36.01M* | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2018-09-30 | Rolling | (m) | -$33.88M* | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2018-06-30 | Rolling | (m) | -$30.48M* | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2018-03-31 | Rolling | (m) | -$27.07M* | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2017-12-31 | Reported | (m) | -$26.15M | (m) | (m) | (m) | $912.00K | -$25.84M | (m) | $29.83M | (m) | (m) |
| 2017-12-31 | Rolling | (m) | -$26.15M* | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Gossamer Bio, Inc. (GOSS) | United States | $5.355B | -0.65 |
| Oruka Therapeutics, Inc. (ORKA) | United States | $5.663B | -43.76 |
| PTC THERAPEUTICS, INC. (PTCT) | United States | $5.199B | -177.07 |
| Travere Therapeutics, Inc. (TVTX) | United States | $5.712B | -123.10 |
| Mirum Pharmaceuticals, Inc. (MIRM) | United States | $5.798B | -8.81 |
| Dianthus Therapeutics, Inc. /DE/ (DNTH) | United States | $5.082B | -27.79 |
| Erasca, Inc. (ERAS) | United States | $5.073B | -19.96 |
| Veradermics, Inc (MANE) | United States | $4.839B | |
| Amneal Pharmaceuticals, Inc. (AMRX) | $6.326B | 25.62 | |
| Liquidia Corp (LQDA) | United States | $6.347B | 51.23 |